Blood plasma concentrations may be increased when combined with CYP3A4 inhibitors, possibly leading to more side effects. This has been clinically verified for ketoconazole, which increases<unk>  exposure by a factor of 9, and is also expected for other 3A4 inhibitors such as grapefruit juice. Co-administration of CYP3A4 inducers like rifampicin or St. John's wort can reduce plasma levels of<unk>  and its active metabolite, and consequently decrease the effects of the drug. For rifampicin, the reduction was sixfold in a study.
Lurasidone
Rimonabant
Pirfenidone
Belinostat
Pirlindole
Family therapy
Lorpiprazole
Chlortalidone